Legal aid may ease burden for cancer caregivers
NCT ID NCT07153016
First seen Jun 26, 2026 · Last updated Sep 18, 2026 · Updated 2 times
Summary
This pilot study offers free legal services to caregivers and patients dealing with advanced colorectal cancer. The goal is to see if early legal support can reduce financial and emotional stress. Twenty patient-caregiver pairs will receive personalized legal help from a nonprofit, and researchers will check if this approach is practical and helpful over three months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- free legal care services
- What this could lead to
- If successful, this could show that providing free legal help early on reduces stress and financial strain for caregivers of colorectal cancer patients.
- What could go wrong
- This is a very small pilot study with only 20 participants, so results may not apply to everyone. It also focuses on feasibility, not proven benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Colorectal Cancer Patient Inclusion Criteria: * Diagnosis of advanced stage (Stage III or Stage IV) colorectal cancer within the past 3 months. * Initiated or planning to initiate systemic cancer therapy. * Able to identify a caregiver for study participation. * Estimated life expectancy of over 6 months in the opinion of the treating oncologist. * 18 years of age or older at the time of consent. * Able to understand, speak, read, and write in English. * Able to provide voluntary written consent prior to the performance of any research related activity. Caregiver Inclusion Criteria: * 18 years of age or older at the time of consent. * Identified as a caregiver by a colorectal cancer patient. * Able to understand, speak, read, and write in English. * Able to provide voluntary written consent prior to the performance of any research related activity. Exclusion Criteria: * Lacks capacity to consent/diminished capacity to consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Caregiver burden are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- A 2.2 mm scope could spot cancerous tissue in minutes, not days
- The gatekeepers of tumors: scientists probe how blood vessels let immune cells in
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers